MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jac/dkt234

Медицинская библиотека · The Journal of antimicrobial chemotherapy · 2013

Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.

Hope R, Blackburn R M, Verlander N Q, Johnson A P, Kearns A, Hill R, Hopkins S, Sheridan E, Livermore D M, Vancomycin Outcome Study Group, UK Clinical Infection Research Group

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

UNLABELLED: Received 29 November 2012; returned 20 February 2013; revised 16 May 2013; accepted 18 May 2013

OBJECTIVES

Raised vancomycin MICs have been associated with poor outcomes for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in the USA and mainland Europe. We investigated if this also applies in the UK, where EMRSA-15 (clonal complex 22) dominates.

METHODS

Isolates from UK patients receiving vancomycin therapy for MRSA bacteraemia in 2008-10 were collected, along with clinical details. Outcomes (i.e. patient survival or bacteraemia resolution) were reported 28 days after vancomycin therapy ended. The relationship between clinical outcome and MIC--as determined by CLSI and BSAC agar dilution methods--was assessed.

RESULTS

Among 228 MRSA bacteraemias, 82% were caused by EMRSA-15; 65% of the patients were male and the median age was 70.5 years. MICs correlated between methods, but CLSI agar dilution testing gave a mode at 1 mg/L with only 12% of results either side, whereas the BSAC method gave a mode straddling 0.7-1 mg/L with <4% outliers. Twenty-three percent of patients died, with MRSA contributory in half; another 17% had unresolved bacteraemia at 28 days. Neither death nor unresolved bacteraemia was significantly associated with higher vancomycin MICs by either method. Rifampicin co-therapy had no quantifiable effect on outcome. The patient's age was the only significant correlate of patient outcome (P < 0.01); the underlying medical condition of the patient was important for the resolution of bacteraemia (P < 0.01), though not for overall mortality.

CONCLUSIONS

Subtle vancomycin MIC differences did not correlate with worse outcomes for vancomycin monotherapy or for vancomycin/rifampicin co-therapy in MRSA bacteraemia. Regardless of the exact MIC-outcome relationship, detecting such small MIC differences seems unlikely to be reliable in routine laboratories.

Для цитирования: Hope R, Blackburn R M, Verlander N Q, Johnson A P, Kearns A, Hill R, Hopkins S, Sheridan E, Livermore D M, Vancomycin Outcome Study Group, UK Clinical Infection Research Group. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.. The Journal of antimicrobial chemotherapy. 2013. DOI: 10.1093/jac/dkt234.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.